An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
AtriCure, Inc. (Nasdaq: ATRC) announced the release of its fourth quarter and full year 2023 financial results on February 15, 2024. The company will host an audio webcast to discuss the results and will also participate in investor meetings at the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13, 2024.
Positive
None.
Negative
None.
MASON, Ohio--(BUSINESS WIRE)--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024.
AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Thursday, February 15, 2024, to discuss its fourth quarter and full year 2023 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir.atricure.com/events-and-presentations/events.
AtriCure’s management is also scheduled to host investor meetings at the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13, 2024, in Snowbird, Utah.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
AtriCure will release its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024.
The ticker symbol for AtriCure is ATRC.
The audio webcast will be available at https://ir.atricure.com/events-and-presentations/events.
AtriCure's management is scheduled to host investor meetings at the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13, 2024, in Snowbird, Utah.
atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.
